Cure of incurable lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue SUPPL. 2, 2006, Pages

  DeNardo, Gerald L ^a   Sysko, Vladimir V ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Lymphoma; Radioimmunotherapy; Radionuclide

Indexed keywords

ANTIBODIES; DRUG PRODUCTS; IMMUNOLOGY; ONCOLOGY; RADIOISOTOPES; RADIOTHERAPY;

LYMPHOMA; MONOCLONAL ANTIBODY (MAB); RADIOIMMUNOTHERAPY;

PATIENT TREATMENT;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM 225; ANTIGEN; ANTINEOPLASTIC AGENT; BISMUTH 213; CD20 ANTIBODY; CHELATING AGENT; COPPER 64; COPPER 67; DRUG CARRIER; EPITOPE; EPRATUZUMAB; HLA ANTIBODY; HLA DR ANTIGEN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN FRAGMENT; INDIUM 111; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3 I 131; MONOCLONAL ANTIBODY LYM 1; ONCOLYM; PENTETIC ACID DERIVATIVE; RADIOISOTOPE; RITUXIMAB; TOSITUMOMAB I 131; YTTRIUM 90;

ARTICLE; B CELL LYMPHOMA; BIOMIMETICS; BLEEDING; BLOOD TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONJUGATE; CYTOPENIA; DOSIMETRY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; HAIR LOSS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISOTOPE LABELING; LYMPHOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT COMPLIANCE; PATIENT SAFETY; PERFORMANCE; PRIORITY JOURNAL; RADIATION DOSE; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; SEPSIS; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; YTTRIUM RADIOISOTOPES;

EID: 33748451448     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.06.038     Document Type: Article

References (66)

1. Knox S.J., Sutherland W., and Goris M.L. Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters. Radiat Res 135 (1993) 24-31
2. Ettinger D.S., Dragon L.H., Klein J., et al. Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer. A case report. Cancer Treat Rep 63 (1979) 131-134
3. DeNardo S.J., DeNardo G.L., O'Grady L.F., et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiopharm 1 (1988) 17-33
4. DeNardo S.J., DeNardo G.L., O'Grady L.F., et al. Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers 2 (1987) 49-53
5. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346 (1995) 336-340
6. Weiden P.L., Breitz H.B., Press O., et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother Radiopharm 15 (2000) 15-29
7. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 2453-2463
8. 90Y-labeled HLA-DR antibodies. Clin Cancer Res 11 (2005) 7075-7079
9. Macklis R.M., Beresford B.A., Palayoor S., et al. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Radiat Oncol Biol Phys 27 (1993) 643-650
10. 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm 16 (2001) 213-225
11. Ghobrial I., and Witzig T. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology 18 (2004) 623-630
12. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
13. Witzig T.E., White C.A., and Gordon L.I. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 1263-1270
14. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3793-3803
15. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3262-3269
16. Kaminski M., Tuck M., and Regan D. High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with Tositumomab and Iodine I-131 Tositumomab (Bexxar). Blood 100 (2002) 356a
17. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14 (1996) 1974-1981
18. 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5 (1999) 3281s-3286s
19. Knox S.J., Goris M.L., Trisler K., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 (1996) 457-470
20. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16 (1998) 3246-3256
21. 131I-Lym-1 antibody. Cancer Biother Radiopharm 13 (1998) 239-254
22. DeNardo G.L., Schlom J., Buchsbaum D.J., et al. Rationales, evidence and design considerations in multiple dose (fractionated) radioimmunotherapy. Cancer 94 (2002) 1332-1348
23. Borghaei H., Wallace S., and Schilder R.J. Factors associated with toxicity and response to Yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 5 (2004) 16-21
24. 131I-Lym-1 as a model. Cancer 73 Suppl (1994) 1038-1048
25. Schenkein D., Leonard J., and Harwood S. Interim safety results of Bexxar in a large multicenter expanded access study. Proc ASCO 20 (2001) 285a
26. Ansell S.M., Ristow K.M., and Habermann T.M. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3885-3890
27. Wahl R.L., Tidmarsh G., Kroll S., et al. Successful re-treatment of non-Hodgkin's lymphoma (NHL) with iodine-131 Anti-B1 antibody. Proc Am Soc Clin Oncol 17 (1998) 40a
28. Kaminski M., Zasadny K., Francis L., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14 (1996) 1974-1991
29. Conti P.S., White C.A., Pieslor P., et al. The role of imaging with In-111-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: Results from a Zevalin imaging registry. J Nucl Med 46 (2005) 1812-1818
30. Liu C., DeNardo G.L., Tobin E., et al. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and rituximab) on human lymphoma cells. Cancer Biother Radiopharm 19 (2004) 545-561
31. Leonard J.P. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (Epratuzumab, an anti-CD22 monoclonal antibody) and HuID10 (Apolizumab). Semin Oncol 29 (2002) 81-86
32. Press O.W., Shan D., Howell-Clark J., et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56 (1996) 2123-2129
33. 111In-labeled monoclonal antitumor antibodies in normal animals and nude-mouse human tumor models. Cancer Res 43 (1983) 5347-5355
34. 131I. J Nucl Med 42 (2001) 967-974
35. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin Cancer Res 5 (1999) 3292s-3303s
36. 131I-labeled Lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 5 (1999) 533-541
37. DeNardo G.L., DeNardo S.J., O'Donnell R.T., et al. Are radiometal-labeled antibodies better than Iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma 1 (2000) 118-126
38. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 41 (2000) 952-958
39. Michel R.B., Ochakovskaya R., and Mattes M.J. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: Importance of using residualizing radiolabels. Clin Cancer Res 8 (2002) 2632-2639
40. McDevitt M.R., Ma D., Lai L.T., et al. Tumor therapy with targeted atomic nanogenerators. Science 294 (2001) 1537-1540
41. Kennel S.J., Stabin M., Roeske J.C., et al. Radiotoxicity of Bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res 151 (1999) 244-256
42. Bodei L., Kassis A.I., Adelstein S.J., et al. Radionuclide therapy with iodine-125 and other Auger-electron-emitting radionuclides: Experimental models and clinical applications. Cancer Biother Radiopharm 18 (2003) 861-877
43. 125I in mammalian cells. Radiat Res 111 (1987) 305-318
44. McDevitt M.R., Sgouros G., Finn R.D., et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25 (1998) 1341-1351
45. Kassis A.I. Invited commentary: Cancer therapy with Auger electrons: Are we almost there?. J Nucl Med 44 (2003) 1479-1480
46. Siegel J.A., and Stabin M.G. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 35 (1994) 152-156
47. DeNardo G.L., Kroger L.A., DeNardo S.J., et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 73 (1994) 1012-1022
48. 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 44 (2003) 77-84
49. Chinn P.C., Leonard J.E., Rosenberg J., et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 15 (1999) 1017-1025
50. DeNardo G.L., Kroger L.A., Meares C.F., et al. Comparison of 1,4,7,10-tetraazacyclododecaine-N,N′,N″,N‴-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. Clin Cancer Res 4 (1998) 2483-2490
51. DeNardo G.L., DeNardo S.J., Peterson J.J., et al. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin Cancer Res 9 10 Pt. 2 (2003) 3865S-3872S
52. Kukis D.L., Novak-Hofer I., and DeNardo S.J. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother Radiopharm 16 (2001) 457-467
53. Sharkey R.M. The direct route may not be the best way to home. J Nucl Med 46 (2005) 391-394
54. Axworthy D.B., Reno J.M., Hylarides M.D., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 97 (2000) 1802-1807
55. Press O.W., Eary J.F., Gooley T., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96 (2000) 2934-2942
56. Weiden P.L., and Breitz H.B. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol 40 (2001) 37-51
57. Press O.W., Corcoran M., Subbiah K., et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98 (2001) 2535-2543
58. Balhorn R., Perkins S.J., Burke P.A., et al. Development of synthetic high affinity ligands that bind to a structural epitope on the tumor cell receptor HLA-DR10. [Abstract]. Proc Am Assoc Cancer Res 46 (2005) 902
59. Balhorn R., Perkins S.J., Burke P.A., et al. Novel selective high affinity ligand (SHAL) "antibody mimics" for lymphoma/leukemia imaging and therapy. [Abstract]. J Nucl Med 45 (2004) 39
60. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
61. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
62. DeNardo G.L., and O'Donnell R.T. Radiolabeled Lym-1 antibody therapy in lymphoma. Biol Ther Lymphoma 2 (1999) 8-13
63. DeNardo G.L. Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. Semin Oncol 32 (2005) 27-35
64. Press O.W., Eary J.F., Badger C.C., et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7 (1989) 1027-1038
65. Parker B.A., Vassos A.B., Halpern S.E., et al. Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal antibody. Cancer Res [Suppl] 50 (1990) 1022s-1028s
66. Henry N., and Wagner Jr. M.D. 2004 SNM Highlights Lecture: Creating lifetime images of health and disease. J Nucl Med 45 (2004) 11N-41N